Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier.

ABSTRACT: Brain tumors are one of the leading causes of cancer related death in both the adult and pediatric patient population. Gliomas represent a cohort of brain tumors derived from glial cell lineages which include astrocytomas, oligodendrogliomas and glioblastomas (GBMs). These tumors are known to grow aggressively and have a high lethality with GBM being the most aggressive tumor in this group. Currently, few treatment options exist for GBM outside of surgical resection, radiation therapy and chemotherapy. While these measures have been shown to marginally improve patient survival, patients, especially those diagnosed with GBM, often experience a recurrence of their disease. Following disease recurrence, treatment options become more limited as additional surgical resections can pose life thre

SUBMITTER: Frederico SC 

PROVIDER: S-EPMC9981631 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature